West Virginia will use the U.S. Postal Service and an online account this summer to…
View More Who Doesn’t Text in 2022? Most State Medicaid Programs
Home »
Desperate for Cash: Programs for People With Disabilities Still Not Seeing Federal Funds
LILBURN, Ga. — Matthew Southern, 35, who has intellectual and developmental disabilities, is able to…
View More Desperate for Cash: Programs for People With Disabilities Still Not Seeing Federal Funds
Hormone Blocker Sticker Shock — Again — As Patients Lose Cheaper Drug Option
Sudeep Taksali thought he’d won his battle to avoid a steep price tag on a…
View More Hormone Blocker Sticker Shock — Again — As Patients Lose Cheaper Drug Option
Mandatory Vaccines for Health Care Workers Might Upend Nurses’ Training
Kaitlyn Hevner expects to complete a 15-month accelerated nursing program at the University of North…
View More Mandatory Vaccines for Health Care Workers Might Upend Nurses’ Training
As Democrats Bicker Over Massive Spending Plan, Here’s What’s at Stake for Medicaid
Hours after the Supreme Court in 2012 narrowly upheld the Affordable Care Act but rejected…
View More As Democrats Bicker Over Massive Spending Plan, Here’s What’s at Stake for Medicaid
Colorado Clinic’s Prescription for Healthier Patients? Lawyers
COMMERCE CITY, Colo. — In her 19 years of living with cerebral palsy, scoliosis and…
View More Colorado Clinic’s Prescription for Healthier Patients? Lawyers
Beneficiarios de Medicaid se vacunan mucho menos contra covid
Los beneficiarios de Medicaid se están vacunando contra covid-19 a tasas mucho más bajas que…
View More Beneficiarios de Medicaid se vacunan mucho menos contra covid
FDA Approves Octapharma’s Octagam 10% for Adult Dermatomyositis
PARAMUS, N.J.–(BUSINESS WIRE) July 20, 2021 –The U.S. Food and Drug Administration (FDA) has granted…
View More FDA Approves Octapharma’s Octagam 10% for Adult Dermatomyositis
FDA Approves Kerendia
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with…
View More FDA Approves Kerendia
FDA Approves Camcevi
FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer TAIPEI, May 26,…
View More FDA Approves Camcevi